USFDA concludes inspection at Cipla’s manufacturing facility in Bengaluru

14 Nov 2024 Evaluate

The United States Food and Drug Administration (USFDA) has concluded the inspection at Cipla’s manufacturing facility in Virgonagar, Bengaluru. The inspection was conducted from 7th - 13th November 2024.

On conclusion of the inspection, the Company received 8 observations in Form 483. The Company will work closely with the USFDA and remains committed to address these observations comprehensively within stipulated time.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1465.65 -5.70 (-0.39%)
21-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1777.65
Dr. Reddys Lab 1194.55
Cipla 1465.65
Lupin 2043.30
Zydus Lifesciences 944.25
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.